Skip to main content
. 2023 Mar 7;7(13):3169–3179. doi: 10.1182/bloodadvances.2022009040

Figure 3.

Figure 3.

Multivariate Cox regression. (A) TTFT and (B) OS. Note that only TP53 mutations with VAF >10% were considered.